<DOC>
	<DOC>NCT00568997</DOC>
	<brief_summary>This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.</brief_summary>
	<brief_title>10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>males and females greater than or equal to 2 years and less than or equal to 17 years at enrollment diagnosis of atopic dermatitis (confirmed by treating physician) applied pimecrolimus cream 1 % 6 weeks out of past 24 weeks past or present history of systemic malignancy, skin malignancy, or lymphoproliferative disease past or present use of oral immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Atopic dermatitis, eczema, children, pediatric patients, pimecrolimus, malignancy, registry</keyword>
</DOC>